Oncolytics Biotech company info

What does Oncolytics Biotech do?
Oncolytics Biotech (TSX:ONC), (NASDAQ:ONCY) focuses on the development of oncology therapies by leveraging the power of immunotherapy and viral therapy to target cancer cells directly. This pioneering approach seeks to transform cancer treatment by harnessing the body's immune system to fight tumors more effectively. Currently, their flagship project revolves around pelareorep, an intravenously delivered immuno-oncolytic virus showing promise in multiple clinical trials across various cancer types. The objective of Oncolytics Biotech is to continue advancing these studies, aiming to provide new, effective treatment options for patients battling cancer. Their efforts are directed towards achieving significant milestones in cancer therapy, contributing to the broader goal of improving patient outcomes and quality of life.
Oncolytics Biotech company media
Company Snapshot

Is Oncolytics Biotech a public or private company?

key
Ownership
Public

How many people does Oncolytics Biotech employ?

people
Employees
36

What sector is Oncolytics Biotech in?

pie chart
Sector
Health Care

Where is the head office for Oncolytics Biotech?

location pin
Head Office
Calgary, Canada

What year was Oncolytics Biotech founded?

founded flag
Year Founded
1998
What does Oncolytics Biotech specialise in?
/Cancer Therapeutics /Reolysin Innovation /Clinical Studies /Vaccine Development /Targeted Therapy /Pharmaceutical Research

What are the products and/or services of Oncolytics Biotech?

Overview of Oncolytics Biotech offerings
REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.
Clinical collaborations with big pharma to evaluate REOLYSIN in combination therapies for various cancers.
Research on enhancing the effectiveness of immunotherapies in cancer treatment through the use of REOLYSIN.
Development of biomarker strategies to identify patient populations most likely to benefit from their therapies.
Exploratory projects on the use of REOLYSIN for pediatric cancers.
Initiatives to expand the application of their technology into veterinary medicine.

Who is in the executive team of Oncolytics Biotech?

Oncolytics Biotech leadership team
  • Dr. Matthew C. Coffey M.B.A., Ph.D.
    Dr. Matthew C. Coffey M.B.A., Ph.D.
    President, CEO & Director
  • Mr. Kirk J. Look C.A., CA
    Mr. Kirk J. Look C.A., CA
    Chief Financial Officer
  • Dr. Thomas C. Heineman M.D., Ph.D.
    Dr. Thomas C. Heineman M.D., Ph.D.
    Chief Medical Officer
  • Ms. Allison  Hagerman P.Eng., P.M.P.
    Ms. Allison Hagerman P.Eng., P.M.P.
    Vice President of Product Development
  • Ms. Amy Goodowitz Levin
    Ms. Amy Goodowitz Levin
    Vice President of Clinical Operations
  • Jon  Patton
    Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen BBA, C.M., FCA, LLD, MBA
    Mr. John Mark Lievonen BBA, C.M., FCA, LLD, MBA
    Consultant